| Popis: |
To assess safety of COVID-19 vaccination in pediatric patients with immune-mediated inflammatory disease (IMID) METHODS: Subjects 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine to assess side effects within one week of vaccination, current medications, and COVID-19 testing after vaccination. Charts were reviewed for COVID-19 polymerase chain reaction and IgG response to SARS-CoV-2 spike protein results, and for disease flare during the study period.Among 190 enrolled subjects, 71% were female, with median age 17 (range 6-21) years. The most common diagnosis was juvenile idiopathic arthritis/rheumatoid arthritis (55%). 78% of subjects were taking immunosuppressive medication. At least one side effect was reported in 65% of subjects after any dose of the vaccine; with side effects in 38%, 53%, and 55% of subjects after the first, second, and third vaccine doses, respectively. The most common side effects were injection site pain (59%), fatigue (54%), and headache (39%). No anaphylaxis or myocarditis was reported. Three subjects (2%) experienced disease flare.In our cohort of pediatric patients with IMID, observed side effects were found to be mild and disease flare rates were found to be low following COVID-19 vaccination. |
Plný text